Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Specificity factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Specificity factor. Displaying page 1 of 1.
    EudraCT Number: 2018-002292-18 Sponsor Protocol Number: 7569 Start Date*: 2019-05-24
    Sponsor Name:University Hospital of Montpellier
    Full Title: CT air-trapping characterization for the early identification of Benralizumab responders among eosinophilic asthma patients
    Medical condition: The study population corresponds to severe eosinophilic asthma patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006295-17 Sponsor Protocol Number: MedTrace-002 Start Date*: 2022-04-08
    Sponsor Name:MedTrace Pharma
    Full Title: A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Con...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10006896 CAD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005786-60 Sponsor Protocol Number: FET-PET-2010 Start Date*: Information not available in EudraCT
    Sponsor Name:Charité Universitaetsmedizin Berlin
    Full Title: A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours
    Medical condition: Children and adolescents with a primary brain tumour after first line therapy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004128-22 Sponsor Protocol Number: NP22002 Start Date*: 2009-04-08
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: An exploratory study to evaluate the biological activity of R1507, a human monoclonal antibody, antagonist of the insulin-like growth factor receptor (IGF-1R) in women with operable breast cancer
    Medical condition: Female patients with operable breast cancer, fulfilling the following criteria.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006204 Breast carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002526-23 Sponsor Protocol Number: 68GaPET-Meningioma-2013 Start Date*: 2014-02-12
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Impact of 68Ga-DOTAOTC PET for diagnosis of newly diagnosed or recurrent meningiomas
    Medical condition: Based on the finding that meningiomas express somatostatin-receptor 2 (SSTR2), PET imaging with SSTR ligands like 68Ga-DOTATOC has been proposed as a more specific method. Currently, the role of SS...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000514-21 Sponsor Protocol Number: AG-PH3 Start Date*: 2007-01-02
    Sponsor Name:CIS bio International
    Full Title: Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99mTc-White Blood Cells in diagnosing infection/inflammation by immunoscintigraphy in peri...
    Medical condition: Patients with suspected or documented osteomyelitis in the peripheral skeleton including patients with loosening of joint prosthesis or diabetic foot. At least one of following signs or symptoms is...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2022-002485-32 Sponsor Protocol Number: CTRIAL-IE-22-01 Start Date*: 2023-03-07
    Sponsor Name:Cancer Trials Ireland
    Full Title: Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach...
    Medical condition: HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005674-61 Sponsor Protocol Number: MSB-RA002 Start Date*: 2013-09-11
    Sponsor Name:Mesoblast, Inc
    Full Title: A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-na...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) EE (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-003381-40 Sponsor Protocol Number: BED-PSMA-301 Start Date*: 2020-06-22
    Sponsor Name:Blue Earth Diagnostics Ireland Ltd.
    Full Title: A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FI (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004108-44 Sponsor Protocol Number: PREMETHEP Start Date*: 2016-02-11
    Sponsor Name:Centre Georges-François Leclerc
    Full Title: PREMETHEP : Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an early predictive factor of overall survival in patients with advanced h...
    Medical condition: Hepatocellular carcinoma (HCC) is the 3rd cause of death by cancer. For patients with inoperable advanced HCC, systemic therapy with Sorafenib (Nexavar®) is the only therapeutic with proven surviva...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001625-16 Sponsor Protocol Number: PBI-4050-ATX-9-05 Start Date*: 2015-10-29
    Sponsor Name:ProMetic BioSciences Inc.
    Full Title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström...
    Medical condition: Alström Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10068814 Alstrom syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003413-18 Sponsor Protocol Number: IM101 Start Date*: 2014-05-13
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's and St. Thomas' NHS Foundation Trust
    3. Leiden University Medical Center
    Full Title: Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept.
    Medical condition: The target population for therapeutic intervention will be subjects who carry serum autoantibodies (antibodies to citrullinated protein antigens – ACPA; rheumatoid factor – RF) and who have joint p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10003239 Arthralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002690-35 Sponsor Protocol Number: OEV123 Start Date*: 2017-05-08
    Sponsor Name:Scandinavian Biopharma AB
    Full Title: A randomized, placebo-controlled phase IIb (OEV 123) study to evaluate safety, immunogenicity, diagnostic methodology, and estimate vaccine efficacy of an oral enterotoxigenic Escherichia coli (ET...
    Medical condition: Healthy voluteers (prevention of diarrheal disease due to infection with enterotoxigenic E. coli [ETEC])
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10054242 Escherichia coli infection LLT
    19.1 100000004862 10044552 Traveller's diarrhea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-001054-96 Sponsor Protocol Number: 000013/BT Start Date*: 2020-03-19
    Sponsor Name:Bone Therapeutics S.A.
    Full Title: Phase IIb, Placebo-Controlled, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB) Single Implantation in Tibial Fracture
    Medical condition: Tibial fracture considered at risk of DU/NU (based on the combination of risk factors documented to be associated with increased proportion of DU/NU).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10043827 Tibia fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing) DE (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) ES (Ongoing) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001975-17 Sponsor Protocol Number: N/A Start Date*: 2022-03-08
    Sponsor Name:Queen Mary University of London
    Full Title: A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer
    Medical condition: Unresectable locally advanced or metastatic urothelial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003940-30 Sponsor Protocol Number: NO21157 Start Date*: 2008-05-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarc...
    Medical condition: Ewing’s sarcoma and other sarcoma subtypes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015560 Ewing's sarcoma LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:12:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA